We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Trouble is that story was written on 10th Feb 21!!!
Hi Shareguard, that is a very interesting observation, which might also explain the lack of buying interest from big pharm....they want to buy a products in general which they can see a pipeline from, buying a platform is a bit different and often different means they do not understand and therefore is not what they look for when making acquisitions.
Thanks to Burble for this post
May I add to Chester's post. For context, I hold a PhD which focussed on the development of antibody therapeutics for melanoma and cervical cancer and still work within the cancer research sector.
Scancell's pipeline is different to other biotechs and is strengthened by the fact that we are not specifically talking about individual products (think individual antibodies, or small-molecule therapeutics). We are talking about adaptable platforms.
Immunobody is a DNA based platform which has the ability to produce high-avidity T-cells to kill infected/cancer cells. Being a DNA based platform it is easy to produce a range of products from - so within a relatively short time a new Immunobody construct targeting a different cancer target or infectious disease target could be generated. Furthermore, the cost of DNA production is small and the product has high stability and a long shelf life meaning high profit margins/low costs.
Moditope is slightly different, but again is a platform based product - this time targeting stress-inducted post-translational modification produced by cancer cells. This has the potential to have low off-target side effects and also target large numbers of cancers.
Avidimab is another product and platform, which can be used to enhance antibodies and their direct cell killing efficiency. This means it can be added to any antibody currently on the market and in development which could improve their effectiveness. This could be licenced to any number of pharma companies developing antibody therapeutics.
Add to all of that we have the anti-glycan monoclonal antibodies. These are more stand along products on their own and have specific functions/targets for each one. These could be valuable as single entity products or as a package.
As a pipeline, what stands out for Scancell vs. other pharma/biotech start ups is the fact that the bulk of their products are platforms. This means they have almost infinite scope to generate new therapies once the platform is proved to work. So whilst there is risk with any product and platforms are no different, once one of these makes it through trials to the clinic, the platform is validated and so any number of 'flavours' of that platform, targeting any number of targets becomes available. Covidity validates Immunobody and Avidimab and a new needle-free delivery system in a single set of trials. SCIB1 trials validates immunobody in cancer and the new Moditope trial (esp. phase 2) is 4 hard to treat cancer trials in one.
If you compare this to a lot of biotechs/pharma they put all their eggs in a single basket with a single product. If that fails, it's back to the drawing board. If it works, many companies will buy that product and incorporate it into their own portfolio. Scancell platforms if validated could be v.v.valuable especially if licenced out to any number of players in the field of infectious disease or oncology.
Recommend (62
Morning they are up early retweeting NY Post article about Universal Covid Vax ready for roll out in 2022 to protect vs new variants
Just seen this news story on Sky News and thought it was worth sharing here.
http://news.sky.com/story/covid-19-new-vaccine-in-development-has-insurance-against-virus-mutations-12217119
Link: https://www.scmp.com/business/companies/article/3096200/fosun-pharma-biontech-see-start-coronavirus-vaccine-trial-china
Article title: Fosun Pharma, BioNTech see start of coronavirus vaccine trial in China an important step before securing marketing approval
https://www.reuters.com/article/us-health-coronavirus-who-vaccine-idUSKCN24P0XT
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/scancell-circular-23-july-2020.pdf
Evening shareguard, great link :)
AvidMab on ProactiveSat 23:19
Nice article the money involved in this mind blowing.
https://www.proactiveinvestors.co.uk/companies/news/921787/scancell-holdings-has-avidimab-paper-published-in-prestigious-cancer-journal-921787.html
cc24601
Posts: 224
Price: 6.60
No Opinion
Lindy is in today's Sunday MirrorToday 07:56
Lindy Durrant is in today's Sunday Mirror. I'm having problems with the link but I've been out and bought a paper and the article and picture is there.
'British Scientists have begun clinical trials on a potentially game changing corona virus vaccine. The vaccine which could provide immunity for six years differs from others currently in development in that it requires far fewer top up jabs because it targets a different part of the immune system. We can also reveal that a leading pharmaceutical company has already agreed to manufacture the vaccine which is being developed at Nottingham University, if it is ruled safe. There are high hopes it will be licensed because the scientists behind it have already used the same technology to develop an effective skin cancer jab. Patients suffering from melanoma received an injection sparking the growth of t cells which recognize and destroy cancer cells. Professor Lindy Durrant who is leading the research said, T cells also kill virally infected cells. This could provide longer term immunity against coronavirus. Our proposal is that you would need to be vaccinated less frequently. If you have good T cell memory, it should last longer. It could potentially last five to six years.
'Because the DNA vaccine has already been shown to be safe and effective in humans, we can fast track'
Professor Durrant's team has already begun testing the jab on mice and human trials could begin in Autumn if investment is secured.
Scancell announces UK regulatory approval to start SCIB1 Phase 2 trial in patients with advanced melanoma
Dosing in UK arm due to commence during this quarter, as planned
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has received all of the UK regulatory, ethical and legal approvals required to initiate the Phase 2 clinical trial to assess the safety and efficacy of SCIB1 in metastatic melanoma patients also receiving the checkpoint inhibitor pembrolizumab (Keytruda). The UK arm of the study is therefore expected to start during the second quarter of this year, as planned.
SCIB1 has completed a Phase 1/2 clinical trial in patients with Stage III/IV malignant melanoma. In this study SCIB1 was shown to have a favourable safety profile with no dose-limiting toxicities and no serious adverse events related to study drug or delivery device. Survival with SCIB1 treatment appears superior to historical survival rates, with 14 of 16 resected patients receiving 2-4 mg doses surviving for more than five years (as reported in February 2018).
Although pembrolizumab is an approved checkpoint inhibitor therapy for advanced melanoma, response to treatment is limited to only a subset of patients (circa 30%). The Phase 2 study is therefore designed to assess whether the addition of SCIB1 treatment will result in an improvement in the tumour response rate, progression-free survival and overall survival in 25 patients with advanced melanoma who are also eligible for treatment with pembrolizumab. SCIB1 will be administered using Ichor's TriGrid® v2.0 electroporation delivery system.
Dr Cliff Holloway, Chief Executive Officer of Scancell, commented:
"This is a major milestone in the clinical advancement of our SCIB1 programme and we look forward to initiating this important Phase 2 study. Our preclinical research has indicated that SCIB1 administration with an immune checkpoint inhibitor has the potential to offer even greater efficacy than when either agent is given alone and this new study is designed to evaluate the safety and efficacy of this approach in patients with inoperable disease.
Great News
Went strait trough on 6.5p limit .. 6.35% spread .
Down 4% Spread 16%
Taverham, just seen your post. In what way does it trivialise the work of teams involved. A prize of £20m was given to three different winners, which is to be used to develop their product.
Scancell beat 143 other entrants to get to the final ten. I think the reaction to not winning outright has been well overdone, surely getting to the final is victory alone. Remember too it is CRUK who are paying for the SCIB 2 Combination trial, lock, stock and barrel. That in itself is a serious peer review of our science.
Hopefully we are seeing support now from a years low. Plenty of news to come.
Afternoon mathsprof, unfortunately not allowed to post NEX trades anymore because of this facility, which is hardly working properly yet.
Never mind, 20k shares bought for £1500 at 7.5 on LSE, M/ap 28.9m, are we seeing a low? Hope so, lol.
xtra, i know you posted on the main BB you didnt want to reply to tit for tat posts, respect that too. If you would though could you identify what you perceive as silly stratagic and management mistakes? I am with you on this one, but also feel we could just as easily be RNSed news which would make us reconsider those feelings? ATB
Understand your feelings xtra, I first bought in at 41p years ago, now averaging 16p.
Hopefully as per the RNS last Monday the two new appointments will help us move quicker to the inflection points we all want to see.
Moditope patent due any day, IND should follow for SCIB1 combo trial shortly as the FDA are back for now anyway.
Now the CRUK Grand Challenge is over I am expecting some developments from our collaborations with BioNTech too. Remember, there is always much we just dont know, fingers crossed.
Board must define these very clearly now. This project needs money and new expertise to become a business rather than a cash sinkhole someone else will run off with. I'm very respectful of the wonderful science but the muddled management is a concern - I'm a LTH, first bought in the 30p region a loooong time ago Want it to work - potentially massive business getting held up by silly strategic and management mistakes. Don't post so often just putting it out there my feelings
resu disapointing but the idea of running a competition trivialises the importance of the work of all the different teams involved.
shows the nex trades - C7 often reports them on main bb
Added this ticker to my watchlist
As mentioned by Bobbust this has just appeared. Something to do with news next week or other things in pipeline?? Thought I'd post here n see what happens to it later.